Trump, AstraZeneca Ink Drug Price-Cutting Accord

The Trump administration has finalized a significant agreement with British pharmaceutical giant AstraZeneca, establishing a “most-favored-nation” drug pricing structure. This landmark deal aims to reduce the cost of prescription medications for Americans enrolled in the government’s Medicaid program while simultaneously shielding the company from potential tariff imposition by the administration. This pact mirrors a similar arrangement recently secured with Pfizer, signaling a broader White House strategy to tackle high pharmaceutical expenses.

White House Secures New Drug Pricing Pact

Announcing the accord from the Oval Office on a Friday evening, then-President Donald Trump opened his remarks by asserting that the deal could have been struck sooner, lamenting, “we were interrupted by a rigged election.” The agreement represents a key step in the administration’s ongoing efforts to pressure drugmakers into lowering prices for U.S. consumers, a persistent issue that has long seen Americans paying significantly more than their counterparts in other developed nations.

Presidential Rhetoric and Company Reaction

Pascal Soriot, AstraZeneca’s Chief Executive Officer, was present at the announcement. He reflected on the arduous negotiation process, stating that discussions with President Trump and his team of officials had “really kept me up at night.” These comments underscore the intense pressure applied by the White House to achieve these pricing concessions. The deals with AstraZeneca and Pfizer are intended to serve as a foundational framework for future agreements as the administration pursues its objective of reducing prescription medicine costs across the United States.

Most-Favored-Nation Model Explained

The core of this agreement dictates that AstraZeneca will offer its “most-favored-nation” pricing to Medicaid. Crucially, this commitment extends to newly introduced drugs, guaranteeing their cost to the U.S. government health plan will align with the lowest prices offered in other developed countries. This mechanism is designed to prevent U.S. consumers from subsidizing lower drug costs elsewhere, a common criticism leveled against the pharmaceutical industry.

President Trump emphasized this point, remarking, “For many years, Americans have paid the highest prices in the world for prescription drugs, by far.” He further suggested that these new arrangements could potentially slash prices to “the lowest price anywhere in the world. That’s what we get.”

Scrutiny Over Price Reduction Claims

However, the President also made highly exaggerated claims regarding the potential savings for American consumers. Trump asserted that the discounted prices could reduce the cost of prescription drugs by an astonishing “up to 1,000%.” This figure quickly drew sharp criticism and fact-checking from experts.

As Daniel Dale of CNN elucidated, “Cutting drug prices by more than 100% would mean that Americans would get paid to acquire their medications rather than paying for them.” This highlights the mathematical impossibility of such a reduction. Health economist Timothy McBride echoed this sentiment, telling the network that Trump’s claims were “just not logical.” McBride further explained that even a 500% price reduction would imply a drug currently costing $100 would effectively become free, with an additional $400 paid to the consumer, a scenario that defies economic principles.

The White House had previously sent letters to 17 prominent drug manufacturers in July, urging them to lower their prices. Pfizer and AstraZeneca are the initial two companies to formalize such agreements,

Source: The Guardian